## Phase III Technical Audit: Scaling to N=125. 
Executive Strategy: The "Efficiency Peak"We are transitioning from an $N=42$ pilot to an $N=125$ Industrial Standard. 
This move is a strategic shift to mathematically "lock in" the established Treatment 2 advantage against biological noise.

### 1.  The Statistical Goal
      1.1 Current State ($N=42$): Located in the "Gamble Zone." Probability of a False Negative (Type II Error) is 57%.
      1.2 Target State ($N=125$): Crossing the 80% Power Threshold. This minimizes the "Error Cost"—the financial risk of scaling an unvalidated treatment.

      1.3 Implementation Roadmap
   
         1.3.1 Step A - Variance Stabilization: Maintain the Robust-t ($M_3$) likelihood. As $N$ grows, the model must guard against "Late-Stage Outliers" (e.g., sensor failures in the $N=80$ to $N=120$ range).
         1.3.2 Step B - Data Drift Monitoring: Run a Cumulative Posterior Update every 20 samples. The 95% High-Density Interval (HDI) must narrow significantly and remain strictly above the 0.0 baseline.
         1.3.3 Step C - Efficiency Audit: Pay the "Robustness Tax" (MCMC compute time) to secure the 86% Reliability Gain.

### 2. Core Achievements: Validating "Outlier Efficacy" : 
      Increasing to $N=125$ achieves three critical engineering objectives:
      2.1 Outlier Dilution: In small samples, one "freak" plant can inflate the mean. 
      2.2 At $N=125$, the mathematical weight of any single outlier is reduced by a factor of $1/N$, forcing the model to rely on typical population behavior.
      2.3 Uncertainty Collapse: This makes our knowledge of growth 86% more stable. We move from a "likely range" to a fixed engineering constant.
      2.4 Robustness Stress-Test: We prove the $M_3$ model can maintain its 30.2% precision gain ($\sigma = 0.90$) even as biological variability increases in a larger batch.

### 3. Phase III Monitoring Protocol
      3.1 Outlier Efficacy Thresholds
      Action: Track the Normality Parameter ($\nu$). If $\nu < 10$, it confirms the presence of heavy-tailed biological outliers.
      Success Metric: If $M_3$ maintains $\sigma \approx 0.90$ despite these outliers, the precision gain is validated.
      The 95% HDI should narrow by 40–50% compared to the pilot.

      3.2 Statistical Stability Audit
<p align="center">
      <img src="/Figures/statistical Stability.png" width="600" alt="Resized Chart Description">
      <br>
</p>
   
      3.3 Real-Time Intervention Triggers
<p align="center">
      <img src="/Figures/RealTimeIntervention.png" width="600" alt="Resized Chart Description">
      <br>
</p>
   
### 4. Final Verdict Requirement
      Upon reaching $N=125$, the final report must include this sign-off:
      STATUS: VALIDATED.
      Treatment 2 superiority is confirmed via $M_3$ architecture at $N=125$ with a finalized noise floor of $\sigma \leq 0.90$. 
      The model is now cleared for industrial-scale deployment.

### 5. Technical Implementation Notes
      5.1 The $\sigma$ Monitor: If $\sigma$ creeps toward the Gaussian 1.29, your outlier mitigation is failing.
      5.2 The Mean ($\mu$) Anchor: The +0.49 advantage is your "Ground Truth." 
      5.3 If deviation exceeds 10%, the $N=42$ pilot was likely biased by sampling noise.
      5.4 Reliability Gain: This is the ultimate metric justifying the extra sampling cost.

      

